



The evolution and comparative neurobiology of endocannabinoid signalling.

Elphick, MR

For additional information about this publication click this link.

<http://qmro.qmul.ac.uk/jspui/handle/123456789/6399>

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact scholarlycommunications@qmul.ac.uk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The evolution and comparative neurobiology of endocannabinoid signalling

Maurice R. Elphick

Queen Mary University of London,
School of Biological & Chemical Sciences,
Mile End Road,
London, E1 4NS, UK

Correspondence to: Prof. M.R. Elphick,
Queen Mary University of London,
School of Biological & Chemical Sciences,
Mile End Road,
London, E1 4NS, UK

Tel: 44 207 882 5290
Fax: 44 208 983 0973
E-mail: M.R.Elphick@qmul.ac.uk

Abstract

CB₁- and CB₂- type cannabinoid receptors mediate effects of the endocannabinoids 2-arachidonoylglycerol (2-AG) and anandamide in mammals. In canonical endocannabinoid-mediated synaptic plasticity, 2-AG is generated postsynaptically by diacylglycerol lipase alpha and acts via presynaptic CB₁-type cannabinoid receptors to inhibit neurotransmitter release. Electrophysiological studies on lampreys indicate that this retrograde signalling mechanism occurs throughout the vertebrates, whilst system level studies point to conserved roles for endocannabinoid signalling in neural mechanisms of learning and control of locomotor activity and feeding. CB₁/CB₂-type receptors originated in a common ancestor of extant chordates, and in the sea squirt *Ciona intestinalis* a CB₁/CB₂-type receptor (CiCBR) is targeted to axons, indicative of an ancient role for cannabinoid receptors as axonal regulators of neuronal signalling. Although CB₁/CB₂-type receptors are unique to chordates, enzymes involved in biosynthesis/inactivation of endocannabinoids occur throughout the animal kingdom. Accordingly, non-CB₁/CB₂-mediated mechanisms of endocannabinoid signalling have been postulated. For example, there is evidence that 2-AG mediates retrograde signalling at synapses in the nervous system of the leech *Hirudo medicinalis* by activating presynaptic TRPV-type ion channels. Thus, postsynaptic synthesis of 2-AG or anandamide may be a phylogenetically widespread phenomenon, and a variety of proteins may have evolved as presynaptic (or postsynaptic) receptors for endocannabinoids.

Key Words

Cannabinoid, anandamide, 2-AG, invertebrate, vertebrate, CRIP1a

1. PREFACE

On March 29th 2001 a review titled “The Neurobiology and Evolution of Cannabinoid Signalling” was published in *Philosophical Transactions of the Royal Society B* (1). It was the first review on cannabinoid signalling to be published in this journal. Since then the field of research on cannabinoid signalling has grown exponentially. Accordingly, the present article is one of fourteen reviews that collectively form an entire journal issue devoted to “Endocannabinoids in nervous system health and disease”. Writing of the 2001 review required a survey of approximately 3000 articles, which was challenging but feasible. Ten years later, by the end of 2011, the PubMed database had over 11,000 articles that could be found using the search term “cannabinoid*”. Clearly, it is no longer feasible to comprehensively review this field of research in a journal article. Even a large book devoted to cannabinoid biology could not cover the range of papers on this topic. Therefore, it is necessary in a review such as this to focus on a specific aspect of cannabinoid biology and the theme here is “The Evolution and Comparative Neurobiology of Endocannabinoid Signalling”, focusing largely on articles that have been published since 2001.

In discussing the evolution and comparative neurobiology of endocannabinoid signalling, it is necessary to first provide an overview of current understanding of mechanisms of endocannabinoid signalling in the group of animals in which this system was discovered – the mammals. It is fitting therefore that on March 29th 2001, three landmark experimental papers were also published that transformed our understanding of endocannabinoid signalling in the mammalian nervous system. Independently, three research groups obtained evidence that postsynaptic depolarisation of principal neurons in the hippocampus or cerebellar cortex triggers postsynaptic synthesis of endocannabinoids, which then act presynaptically to cause CB₁-mediated inhibition of neurotransmitter release (2-4) Thus, a mechanism of synaptic plasticity mediated by retrograde endocannabinoid signalling was discovered. The concept that endocannabinoids might act as retrograde synaptic signalling molecules had been proposed three years earlier based on our neuroanatomical observations (5) and a model of this putative signalling mechanism was presented

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
in the 2001 review article (1). But it was the three other papers published on the 29th March 2001 that converted a hypothesis into a textbook principle. Within a decade, the field of research on endocannabinoid signalling has moved from a marginal position to the centre stage of 21st century neuroscience. So looking back, the 29th March 2001 can be thought of as a turning point for cannabinoid research and indeed it has been referred to as a Dies Mirabilis for the field (6).

2. INTRODUCTION TO ENDOCANNABINOID SIGNALLING

(a) Discovery of CB₁ and CB₂ cannabinoid receptors

The existence of cannabinoid receptors in the brain was first inferred from the stereoselective pharmacological actions of Δ^9 -tetrahydrocannabinol (Δ^9 -THC), the psychoactive constituent of cannabis, and other cannabinoid-type compounds (7). However, demonstration of the existence of specific cannabinoid binding sites in the brain using the radiolabelled cannabinoid ³H-CP-55,940 provided the first solid evidence that cannabinoid receptors exist in the brain (8). Molecular characterisation of a protein that confers cannabinoid binding-sites on rodent brain cell membranes provided the definitive proof of a receptor and revealed a 473-residue G-protein coupled receptor (9), which is now referred to as CB₁. This nomenclature distinguishes CB₁ from a related G-protein coupled receptor known as CB₂, which is predominantly associated with immune cells (10). Thus, in humans and other mammals there are two G-protein coupled cannabinoid receptors, CB₁ and CB₂, and analysis of CB₁-knockout mice and CB₂-knockout mice indicates that these two receptors are largely responsible for mediating the pharmacological effects of Δ^9 -THC in mammals (11-13).

(b) Endocannabinoids and enzymes involved in endocannabinoid biosynthesis and inactivation

The discovery of CB₁ and CB₂ pointed to the existence of endogenous ligands for these receptors and two such “endocannabinoids” have been identified – *N*-arachidonylethanolamide (“anandamide”) and *sn*-2-arachidonoylglycerol (2-AG) (14-16).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2-AG is synthesized in the brain by the enzyme diacylglycerol lipase alpha (DAGL α), which catalyses cleavage of 2-AG from arachidonic acid containing diacylglycerols (DAGs) (17-19). A second diacylglycerol lipase that is related to DAGL α based on sequence similarity has been identified and is known as DAGL β (17). However, whilst DAGL β can catalyse formation of 2-AG *in vitro* (17), comparative analysis of the brain content of 2-AG in DAGL α - and DAGL β -knockout mice indicates that the contribution of DAGL β to 2-AG biosynthesis in adult brain is much less significant compared to DAGL α (18, 19). 2-AG is inactivated by the enzyme monoacylglycerol lipase (MAGL), which cleaves 2-AG into arachidonic acid and glycerol (20-22). Approximately 85% of brain 2-AG hydrolase activity is attributable to MAGL, whilst the remaining 15% is largely attributed to the α/β hydrolases ABH6 and ABH12 (23).

The mechanisms by which anandamide is synthesized in the brain are not yet fully characterised. *In vitro* studies suggested that anandamide may be synthesized by a two-step enzymatic pathway wherein a Ca²⁺-activated *N*-acyltransferase transfers a *sn*-1 arachidonoyl acyl group of a phospholipid onto the amine of phosphatidylethanolamine (PE) to generate *N*-acyl PE (NAPE) and then NAPE is converted by a phospholipase D (NAPE-PLD) into anandamide and phosphatidic acid (24-27). However, the levels of anandamide in brains from NAPE-PLD-knockout mice are not significantly different from wild-type mice, arguing against a role for NAPE-PLD in anandamide biosynthesis in the brain. The levels of long-chain saturated *N*-acylethanolamines are substantially reduced in NAPE-PLD knockout mice though, indicating that the primary function of NAPE-PLD in the brain may be in biosynthesis of these molecules (28). The physiological roles of long-chain saturated *N*-acylethanolamines in the brain are unknown, but localisation of NAPE-PLD in the axons and axon terminals of sub-populations of neurons in the brain has provided a neuroanatomical framework for further investigation of this issue (29).

Other enzymatic pathways have also been implicated in biosynthesis of anandamide (30-35) but, as yet, definite proof that these are involved in *in vivo* production of anandamide in the brain has

Evolution and Comparative Neurobiology

Maurice R. Elphick

not been forthcoming. It is possible that multiple and potentially interacting pathways are involved, which may make it difficult to pinpoint roles for particular enzymes.

Whilst our knowledge of mechanisms of anandamide biosynthesis in the brain remains incomplete, enzymes that catalyse inactivation of anandamide have been identified. In 1996 Cravatt *et al.* identified an enzyme known as fatty acid amide hydrolase (FAAH), which converts anandamide to arachidonic acid and ethanolamine (36) and subsequent analysis of FAAH knockout-mice and mice treated with selective FAAH inhibitors have demonstrated that FAAH has a major role in regulation of anandamide levels in the brain (37, 38). In humans, but not rodents, there is a second FAAH-like enzyme, which is known as FAAH-2 (39). Analysis of the biochemical properties of FAAH-2 reveals that it associated with lipid droplets in cells and hydrolyses anandamide at rates 30-40% of those of FAAH (40). Furthermore, cyclooxygenase-2 (COX-2) also contributes to the metabolism of anandamide in neurons and other cell types (41, 42).

Lastly, evidence for and against the existence of proteins involved in transport of endocannabinoids has been reported (43, 44) and recently it was proposed that a catalytically silent isoform of FAAH (FAAH-like anandamide transporter or FLAT) may drive anandamide transport into neurons (45).

(c) Putative regulators of cannabinoid receptor signalling

The existence of proteins that regulate the activity of G-protein coupled receptors (GPCRs) is well established. These include proteins such as G-protein coupled receptor kinases (GRKs), which phosphorylate serine and threonine residues in GPCR C-terminal of tails following G-protein dissociation, and arrestins, which bind to C-terminally phosphorylated GPCRs and then block interaction with G-proteins and mediate receptor internalisation (46). However, these are generic GPCR-interacting proteins that regulate the activity of many GPCRs. In addition to these generic GPCR-interacting proteins, other proteins that only interact with specific GPCRs have been

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 identified. For example, the melanocortin receptor accessory protein MRAP mediates targeting of
3
4 MC2-type melanocortin receptors to the cell surface in adrenal cells (47-49).
5

6
7 The first report of candidate cannabinoid receptor interacting proteins (CRIPs) was published
8
9 in 2007 (50). Deletion of the C-terminal region of the CB₁ receptor had been found to alter CB₁
10
11 signalling (51) and it was postulated that accessory proteins binding to this region of the receptor
12
13 may modulate CB₁ activity. Using a polypeptide corresponding to the C-terminal 55 residues of the
14
15 CB₁ receptor as bait, a yeast two-hybrid screen was employed to identify potential interacting partner
16
17 proteins expressed in human brain. A 128 residue protein was identified as a positive hit and analysis
18
19 of its sequence revealed that it is encoded by a gene containing four exons (1, 2, 3a and 3b) that is
20
21 subject to alternative splicing, with exons 1, 2 and 3b encoding the 128 residue protein and exons 1,
22
23 2 and 3a encoding a 164 residue protein (50). Biochemical evidence that both the 164-residue
24
25 protein and the 128-residue protein interact with the C-terminal tail of CB₁ was obtained and
26
27 accordingly these two proteins were named cannabinoid receptor interacting protein 1a (CRIP1a)
28
29 and cannabinoid receptor interacting protein 1b (CRIP1b), respectively. Furthermore, co-expression
30
31 of CRIP1a or CRIP1b with CB₁ in superior cervical ganglion neurons revealed that CRIP1a, but not
32
33 CRIP1b, suppresses CB₁-mediated tonic inhibition of voltage-gated Ca²⁺ channels, providing
34
35 evidence of a role for CRIP1a in regulation of CB₁ signalling (50). More recently, it has been
36
37 reported that co-expression of CRIP1a with CB₁ receptors in cultured cortical neurons alters the
38
39 actions of cannabinoids in a neuroprotection assay, inhibiting the neuroprotective effect of a CB₁
40
41 agonist (WIN55,212-2) and conferring responsiveness to the CB₁ antagonist SR141716 as a
42
43 neuroprotective agent (52). These data provide further evidence that CRIP1a may regulate CB₁
44
45 signalling. However, as yet, evidence that CRIP1a regulates CB₁ signalling *in vivo* has not been
46
47 reported and for this we may have to await the characterisation of CRIP1a gene-knockout mice.
48
49
50
51
52
53
54

55
56 ***(d) Endocannabinoid signalling as a mediator of synaptic plasticity in the nervous system***
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Thus far, a catalogue of proteins that act as cannabinoid receptors or regulators of cannabinoid receptor signalling or catalyse biosynthesis/inactivation of endocannabinoids has been presented. However, from a neurobiological perspective our interest is in understanding how these proteins work together at the cellular level to enable neurophysiological mechanisms to operate. The term “cannabinoid or endocannabinoid signalling” first appears in the literature in 1998 (53, 54) but prior to this much was already known about the distribution of the CB₁ receptor in the brain and the effects of cannabinoids on neurotransmitter release. Based on an analysis of the distribution of cannabinoid binding sites (using ³H-CP-55,940 autoradiography) combined with lesion studies and analysis of patterns of CB₁ gene expression (using mRNA in situ hybridisation) it was concluded that the CB₁ receptor is targeted to the axons and axon terminals of neurons in the brain (55-58). This was then confirmed by a series of immunocytochemical studies published in 1998 (5, 59, 60). This presynaptic targeting of CB₁ receptors in neurons was consistent with electrophysiological studies demonstrating that cannabinoids cause inhibition of neurotransmitter release (61). Furthermore, evidence that endocannabinoids are released in response to neuronal stimulation was reported (62), which suggested that endocannabinoids act as intercellular (not intracellular) signalling molecules. A logical extrapolation of these anatomical and physiological observations was that endocannabinoids are synthesized postsynaptically and act as retrograde synaptic signalling molecules (5), which was subsequently proven to be correct.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Depolarisation of principal neurons in several brain regions causes CB₁-mediated inhibition of presynaptic release of the excitatory neurotransmitter glutamate (depolarisation-induced suppression of excitation or DSE) and/or CB₁-mediated inhibition of presynaptic release of the inhibitory neurotransmitter GABA (depolarisation-induced suppression of inhibition or DSI) (2-4). DSE and DSI are not observed in DAGL α -knockout mice, indicating that 2-AG mediates these mechanisms of synaptic plasticity (18, 19). DAGL α is concentrated postsynaptically in dendritic spines that are apposed to CB₁-expressing axon terminals (63), which is consistent with the notion that 2-AG is synthesized postsynaptically but acts presynaptically. The 2-AG degrading enzyme

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MAGL is localised presynaptically in the axons of neurons, most notably in glutamatergic neurons (20, 64) and the duration of DSI and DSE in MAGL-knockout mice is prolonged when compared to wild-type mice, indicating that MAGL controls the temporal dynamics of 2-AG/CB₁-mediated retrograde synaptic signalling (65, 66). Accordingly, the MAGL inhibitor JZL184 also prolongs the duration of DSI and DSE in mice (67).

Endocannabinoid signalling also mediates long-term depression (LTD) of synaptic transmission. For example, stimulation of cortical glutamatergic input to the striatum causes activation of postsynaptic metabotropic glutamate receptors, leading to endocannabinoid/CB₁-mediated long-term depression of transmission at excitatory cortico-striatal synapses (68). Endocannabinoid/CB₁-mediated LTD has subsequently been reported in other brain regions and there is evidence that, as with DSE and DSI, it is postsynaptic formation of 2-AG that mediates this particular form of long-term synaptic plasticity (69).

The physiological roles of anandamide as an endogenous agonist for CB₁ receptors in the central nervous system are currently less well characterised when compared to 2-AG. Evidence that anandamide may also mediate retrograde signalling at synapses has also been reported (70) and it has been suggested that anandamide may mediate tonic endocannabinoid signalling, thereby performing a role that is distinct from the transient stimulated release of 2-AG (71). Furthermore, there is evidence that anandamide may mediate mechanisms of synaptic plasticity via CB₁-independent molecular pathways. Thus, postsynaptic elevation of intracellular anandamide levels is thought to cause LTD via a mechanism mediated by the cation channel TRPV1, which results in internalisation of postsynaptic AMPA-type glutamate receptors (6, 70, 72).

Whilst our knowledge and understanding of the roles of endocannabinoid signalling at the synaptic level have improved dramatically over the last decade, there is still much work to be done in linking processes at this level to the systems level. The CB₁ receptor is widely distributed in the brain but not all neurons express CB₁, so why do particular neural pathways in the brain utilise endocannabinoid signalling to regulate synaptic transmission, whilst others don't. Proximate answers

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

to this question will surely emerge as we learn more about the patterns of electrical activity that trigger synthesis of endocannabinoids in different regions of the brain and the net behavioural consequences of this. However, ultimate answers will only be obtained by comparative analysis of the physiological roles of the endocannabinoid system, which may shed light on how over evolutionary timescales the endocannabinoid system has been recruited as a regulator of neural processes in different lineages. Some roles of the endocannabinoid system in brain function may be ancient and highly conserved; other roles may have evolved more recently as neural adaptations that are unique to particular lineages. If we are to understand endocannabinoid signalling it will be necessary to explore the physiological roles of this system throughout the animal kingdom, and already important insights are beginning to emerge from comparative studies on non-mammalian animals, as discussed below.

3. THE PHYLOGENETIC DISTRIBUTION AND EVOLUTION OF ENDOCANNABINOID SIGNALLING

Canonical endocannabinoid signalling in the mammalian nervous system, as it is currently understood, could be characterised as a process in which postsynaptic formation of 2-AG by DAGL α in response to depolarisation-induced Ca²⁺ elevation or activation of metabotropic receptors coupled via G-proteins to PLC causes inhibition of neurotransmitter release when 2-AG binds to presynaptic CB₁ receptors, with the spatial and temporal dynamics of this signalling mechanism being controlled by presynaptic degradation of 2-AG by MAGL. Thus, in investigating the evolutionary origins of endocannabinoid signalling, one could specifically investigate the phylogenetic distribution DAGL α , MAGL and CB₁-type receptors. However, this would be a rather narrowly defined view of endocannabinoid signalling in the nervous system. It is true to say that at present our understanding of the physiological role of anandamide as an endogenous ligand for CB₁ receptors is incomplete by comparison with 2-AG. Nevertheless, the phylogenetic distribution of

1
2 enzymes involved or implicated in anandamide biosynthesis or inactivation is of interest. Likewise,
3
4 it is important to investigate the phylogenetic distribution of proteins implicated as regulators of CB₁
5
6 signalling such as CRIP1a and CRIP1b, because this may inform understanding of their proposed
7
8 functions. Whilst CB₁ is by far the most abundant cannabinoid receptor in the mammalian nervous
9
10 system, there is evidence that CB₂ may have important roles in neural functions (73) and therefore
11
12 the phylogenetic distribution of CB₂ receptors is also of interest from a neurobiological perspective.
13
14

15
16
17
18 **(a) The phylogenetic distribution of CB₁/CB₂-type cannabinoid receptors**
19

20 As mediators of the pharmacological effects of Δ^9 -THC and the physiological actions of
21
22 endocannabinoids, the G-protein coupled cannabinoid receptors CB₁ and CB₂ are the focal points for
23
24 a phylogenetic survey of endocannabinoid signalling. CB₁ and CB₂ share more sequence similarity
25
26 with each other (~44%) than with any other mammalian G-protein coupled receptors, indicating that
27
28 they originated by duplication of a common ancestral gene (i.e. they are paralogs). Furthermore, the
29
30 relatively low level of sequence similarity shared by CB₁ and CB₂ receptors in mammals is
31
32 suggestive of an evolutionarily ancient gene duplication. Analysis of the phylogenetic distribution of
33
34 CB₁ and CB₂ receptors indicates that the gene duplication that gave rise to these two receptors
35
36 occurred in a common ancestor of extant vertebrates, probably concurrently with a whole-genome
37
38 duplication event. Thus, CB₁ and CB₂ receptor genes can be found in the genomes of non-
39
40 mammalian tetrapod vertebrates (amphibians e.g. *Xenopus tropicalis*; birds e.g. *Gallus gallus*) and in
41
42 bony fish (e.g. the zebrafish *Danio rerio*) (74, 75). Interestingly, in teleosts duplicate copies of CB₁
43
44 or CB₂ genes are found, attributable to a genome-duplication in a common ancestor of teleosts
45
46 followed by subsequent lineage-specific retention/loss of duplicate genes. Thus, in the zebrafish
47
48 *Danio rerio* there is one CB₁ gene and two CB₂ genes, whereas in the puffer fish *Fugu rubripes* there
49
50 are two CB₁ genes and one CB₂ gene. However, the functional significance of the differential
51
52 retention of duplicate CB₁ or CB₂ genes in different teleost lineages is currently unknown (74, 75).
53
54
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

To date there are no published reports of CB₁ and CB₂ genes in the most basal of the extant vertebrate orders – the chondrichthyes (e.g. sharks and rays) and the agnathans (e.g. lampreys and hagfish). However, unpublished genome sequence data are available for the elephant shark *Callorhinchus milii* (<http://esharkgenome.imcb.a-star.edu.sg/>) and the sea lamprey *Petromyzon marinus* (http://genome.wustl.edu/genomes/view/petromyzon_marinus) and in both species a gene encoding a CB₁-type receptor can be found. Interestingly, a CB₂-type receptor gene is not evident in the currently available genome sequence data, which may simply reflect incomplete sequence data or perhaps more interestingly may reflect loss of CB₂ receptor genes in these basal vertebrates.

Genes encoding CB₁/CB₂-type receptors have been found in the invertebrate groups that are most closely related to the vertebrates (urochordates, e.g. CiCBR in *Ciona intestinalis*; cephalochordates, e.g. BfCBR in *Branchiostoma floridae*) but not in the non-chordate invertebrate phyla (74, 76-79). Thus, it appears that CB₁/CB₂-type receptors are unique to the phylum Chordata and as such they have a rather restricted phylogenetic distribution in the animal kingdom.

(b) The phylogenetic distribution of DAG lipases

The antiquity of DAG lipases is evident in the strategy that led to the discovery of the mammalian enzymes DAGL α and DAGL β - the sequence of a DAG lipase originally identified in the bacterium *Penicillium* was used to identify related proteins in BLAST searches of the human genome sequence (17). This indicates that DAG lipases are an ancient enzyme family that originated in prokaryotes. Submission of human DAGL α and human DAGL β as query sequences in BLAST searches of the GenBank protein database reveals orthologs of both isoforms in deuterostomian invertebrates and protostomian invertebrates. Thus, the gene duplication that gave rise to DAGL α or DAGL β dates back at least as far as the common ancestor of extant bilaterian animals.

(c) The phylogenetic distribution of MAG lipase

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 MAG lipase (MAGL) was originally discovered on account of its role in fat metabolism (80)
3
4 and subsequently it was proposed that MAGL may regulate 2-AG levels in the brain (20).
5
6
7 Submission of human MAGL as a query sequence in BLAST searches of the GenBank protein
8
9 database reveals orthologs in a wide range of animal species, including deuterostomian invertebrates,
10
11 protostomian invertebrate and basal invertebrates such as cnidarians (*Nematostella vectensis*) and
12
13 placozoans (*Trichoplax adhaerens*). Therefore, MAGL was present in the common ancestor of
14
15 extant animals. However, there has been loss of MAGL in some lineages; for example, in
16
17 *Drosophila* and other insects. Interestingly, MAGL is also found in poxviruses, which is probably a
18
19 consequence of horizontal gene transfer from host species (81).
20
21
22
23

24
25 ***(d) The phylogenetic distribution of NAPE-PLD as an enzyme implicated in anandamide***
26
27 ***biosynthesis***

28
29 Although analysis of NAPE-PLD knockout mice indicates that NAPE-PLD is not responsible
30
31 for synthesis of the bulk of anandamide in the brain (28), this does not rule out the possibility that
32
33 NAPE-PLD participates in anandamide biosynthesis in other organs and organisms. Therefore, it is
34
35 of interest to determine the phylogenetic distribution of NAPE-PLD with respect to the evolution of
36
37 endocannabinoid signalling. Orthologs of NAPE-PLD are found throughout the animal kingdom, in
38
39 non-mammalian vertebrates, deuterostomian invertebrates (e.g. the sea urchin *Strongylocentrotus*
40
41 *purpuratus*), protostomian invertebrates (e.g. the crustacean *Daphnia pulex* and the nematode *C.*
42
43 *elegans*) and basal invertebrates such as the cnidarian *Nematostella vectensis* and the placozoan
44
45 *Trichoplax adhaerens*. However, as with MAGL, there has been loss of NAPE-PLD in some
46
47 lineages. For example, orthologs of NAPE-PLD are not present in *Drosophila* and other insects, the
48
49 urochordate *Ciona intestinalis* and the cephalochordate *Branchiostoma floridae*. The functional
50
51 significance of NAPE-PLD loss in some animal lineages is currently unknown. However,
52
53 biochemical analysis of species that lack NAPE-PLD may provide useful new insights on NAPE-
54
55 PLD-independent mechanisms of *N*-acylethanolamine biosynthesis.
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(e) The phylogenetic distribution of FAAH and FAAH-2

Analysis of the phylogenetic distribution of FAAH and FAAH2 indicates that the gene duplication that gave rise to these related proteins probably predates the origins of the first animals with nervous systems. However, in addition to the loss of FAAH2 in rodents (see above), there are other examples of lineage-specific loss of FAAH or FAAH2. For example, only a FAAH2 ortholog is found in *Drosophila* and other insects.

(f) The phylogenetic distribution of CRIP1a and CRIP1b

Analysis of the phylogenetic distribution of CRIP1a and CRIP1b in mammals reveals that, whilst CRIP1a is found throughout the mammals, CRIP1b may be unique to catarrhine primates. For example, orthologs of human CRIP1b can be found in the chimpanzee *Pan troglodytes*, the gibbon *Nomascus leucogenys* and the rhesus monkey *Macaca mulatta*. Thus, it appears that exon 3b of the human CRIP1 gene, which is unique to CRIP1b, may have originated relatively recently in mammalian evolution. The functional significance of this is unknown and it will be interesting to investigate the roles of CRIP1b in brain function.

Unlike the restricted phylogenetic distribution of CRIP1b, CRIP1a has a much wider phylogenetic distribution that extends throughout much of the animal kingdom. Indeed orthologs of CRIP1a can be found in basal invertebrates such as the cnidarian *Nematostella vectensis*, indicating that CRIP1a is very ancient protein with origins dating back to the first animals with nervous systems. Accordingly, orthologs of human CRIP1a are found throughout the vertebrates and in deuterostomian invertebrates (e.g. in the cephalochordate *Branchiostoma floridae* and in the hemichordate *Saccoglossus kowalevski*) and protostomian invertebrates (e.g. in the insect *Bombus impatiens* and in the nematode *Caenorhabditis elegans*). This contrasts with the much more restricted phylogenetic distribution of CB₁/CB₂-type cannabinoid receptors, which, as highlighted above, are only found in vertebrates and invertebrate chordates. What this suggests is that CRIP1a is

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 evolutionarily much more ancient than the CB₁ receptor protein that it is thought to interact with. We
3
4 can infer from this that CRIP1a must have other physiological roles in cells in addition to its
5
6 proposed interaction with CB₁ receptors.
7
8
9

10 11 12 13 **4. COMPARATIVE NEUROBIOLOGY OF ENDOCANNABINOID SIGNALLING** 14 15

16 17 18 *(a) Neurobiology of CB₁/CB₂-type endocannabinoid signalling in non-mammalian vertebrates* 19

20 Given that a great deal is now known about the role of endocannabinoid-CB₁ signalling in
21
22 mediating retrograde signalling at synapses in the mammalian brain, it is pertinent to pose the
23
24 question: is there evidence that endocannabinoid-CB₁ mediated retrograde signalling operates at
25
26 synapses in the central nervous systems of non-mammalian vertebrates? Addressing this question
27
28 may shed light on the evolutionary origin of this particular mechanism of synaptic plasticity. Not
29
30 surprisingly, direct evidence from electrophysiological studies comparable to those carried out on
31
32 rodent brain slices is sparse. The strongest evidence can be found in an impressive series of studies
33
34 investigating the roles of endocannabinoid signalling in the spinal neuronal network that controls
35
36 swimming in the lamprey *Lampetra fluviatilis*. Collectively, the data obtained indicate that 2-AG is
37
38 synthesized postsynaptically by neurons in the spinal locomotor network and acts presynaptically to
39
40 inhibit both excitatory and inhibitory neurotransmission via CB₁-mediated mechanisms.
41
42

43
44 Furthermore, nitric oxide and endocannabinoid signalling interact to regulate the
45
46 frequency/amplitude of the locomotor rhythm by differentially modulating excitatory and inhibitory
47
48 inputs to motoneurons (82-85). Thus, it appears that 2-AG/CB₁-mediated regulation of excitatory
49
50 and inhibitory neurotransmission is a highly conserved mechanism throughout the vertebrates.
51

52
53 Consistent with this hypothesis, recent electrophysiological studies have demonstrated that
54
55 endocannabinoid-CB₁ signalling mediates DSE and metabotropic glutamate receptor - induced LTD
56
57 in area X of the zebra finch brain (Thompson and Perkel, 2011). Furthermore, immunocytochemical
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

analysis of CB₁ expression in the nervous systems of non-mammalian vertebrates reveals patterns of expression consistent with axonal targeting and presynaptic sites of action (86-89).

Given the key role that DAGL α has in postsynaptic formation of 2-AG as a mediator of retrograde synaptic signalling in the mammalian CNS, it would be interesting to determine whether DAGL α is located in the somatodendritic compartment of neurons postsynaptic to CB₁-expressing axons in non-mammalian vertebrates. However, whilst the existence of DAGL α in non-mammalian vertebrates is confirmed by comparative analysis of genome sequence data (see above), detailed neuroanatomical analyses of DAGL α expression in the CNS of non-mammalian vertebrates have not yet been conducted.

It is perhaps not surprising that the physiological roles of 2-AG/CB₁-mediated endocannabinoid signalling at the sub-cellular/cellular level are conserved throughout the vertebrates. Are, however, the roles of endocannabinoid signalling also conserved at the system level e.g. with respect to the regions of the CNS where the CB₁ receptor is expressed and the physiological/behavioural processes that the endocannabinoid signalling system regulates? To address this question, we must look to a currently rather limited number of neuroanatomical and behavioural studies of the cannabinoid system in non-mammalian vertebrates.

Developmental analysis of the zebrafish *Danio rerio* reveals CB₁ mRNA expression in cells located in the presumptive preoptic area of the diencephalon at 24 hours post-fertilization (pf) and by 48 hours expression is observed in the telencephalon, the hypothalamus, the tegmentum and the hindbrain (ventral to cerebellum). In adult zebrafish, CB₁ mRNA expression is observed in the anterior region of the telencephalon and in the periventricular medial zone and central zone of the dorsal telencephalon. Expression is also evident in the hypothalamus and posterior tuberculum (diencephalon) and in the torus longitudinalis (mesencephalon) (90). Complementing the use of *in situ* hybridisation techniques by Lam et al. for analysis of CB₁ mRNA expression in *Danio rerio*, Cottone et al. have used immunocytochemical techniques to investigate the distribution of the CB₁ protein in the cichlid *Pelvicachromis pulcher* (86, 91). Immunostained neurons and/or fibres were

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

observed in several brain regions including the telencephalon, the preoptic nucleus, the lateral infundibular lobes of the hypothalamus, the pretectal central nucleus and the posterior tuberculum.

In amphibians, the distribution of CB₁ mRNA in the brain of the rough skinned newt *Taricha granulosa* has been examined using mRNA *in situ* hybridisation methods, revealing a widespread pattern of expression with CB₁ mRNA detected in the telencephalon (olfactory bulb, the pallium and amygdala), the diencephalon (preoptic area and thalamus), the mesencephalon (tegmentum and tectum) and the hindbrain (cerebellum and stratum griseum) (92). Complementing the use of *in situ* hybridisation techniques by Hollis et al. for analysis of CB₁ mRNA expression in *Taricha*, Cesa et al. have used immunocytochemical techniques to investigate the distribution of CB₁ in the brain of *Xenopus laevis*, revealing CB₁-immunoreactive cells and/or fibres in the olfactory bulbs, dorsal and medial pallium, striatum, amygdala, thalamus, hypothalamus, mesencephalic tegmentum and cerebellum (87). CB₁-immunoreactivity is also present in the dorsal and central fields of the *Xenopus* spinal cord, regions that correspond to laminae I-IV and X of the mammalian spinal cord (88).

In birds, CB₁ expression has been analysed in the brain of the chick *Gallus gallus* (93), the zebra finch *Taeniopygia guttata* (89) and the budgerigar *Melopsittacus undulates* (94), revealing some patterns of expression that are strikingly similar to findings in mammals (57, 95). For example, high levels of CB₁ expression are observed in the hippocampus and amygdala and, as in mammals, in the cerebellar cortex the CB₁ gene is expressed in granule cells and the receptor protein is targeted to parallel fibres in the molecular layer.

Detailed descriptions of the distribution of CB₁ receptor expression in the CNS provide valuable frameworks for further investigation of the roles of the endocannabinoid signalling system in non-mammalian vertebrates. However, the number of species analysed thus far are too few to enable any meaningful general conclusions on how the neuroarchitecture the cannabinoid signalling system has been shaped by lineage-specific changes in brain organisation over evolutionary time scales. Nevertheless, the expression of CB₁ in so many different brain regions suggests that

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

endocannabinoid signalling has been a fundamental and widely employed mechanism of synaptic plasticity throughout more than 400 million years of vertebrate brain evolution. Moreover, there is evidence that at least some of the physiological/behavioural roles of endocannabinoid signalling that have been discovered in mammals are also applicable to non-mammalian vertebrates, suggesting evolutionarily ancient origins.

Some of the most striking actions of CB₁ cannabinoid receptor agonists in mammals are dose-dependent modulatory effects on locomotor activity (96). These behavioural effects are consistent with abundant expression of the CB₁ receptor in brain regions involved in initiation (basal ganglia) and co-ordination (cerebellum) of movement (1). Furthermore, consistent with the notion that CB₁ has an evolutionarily ancient role in neural pathways that control movement, Valenti et al. have reported that the CB₁ receptor antagonist AM 251 (1 µg/g body mass) causes a reduction in locomotor activity in the goldfish *Carassius auratus* (97). Behavioural effects of drugs that bind to the CB₁ receptor have also been investigated in an amphibian species, the rough skinned newt *Taricha granulosa*, revealing an inhibitory effect on spontaneous locomotor activity and courtship clasping behaviour (98). Likewise, the cannabinoid WIN 55,212-2 causes inhibition of locomotor activity in the zebra finch (99).

The brain endocannabinoid system is also involved in regulation of appetite and feeding in mammals (100), and again there is evidence that this role may be evolutionarily ancient. A study by Valenti et al. on the goldfish *Carassius auratus* found that food deprivation was accompanied by a significant increase in anandamide (but not 2-AG) in the telencephalic region of the brain and intraperitoneal injection of anandamide (1 pg/g body mass) caused an increase in food intake within 2 h of administration (97). Soderstrom et al. report that in the zebra finch a reduction in food availability causes elevation of 2-AG in the caudal telecephalon and a CB₁-mediated reduction in song-stimulated brain expression of the transcription factor ZENK and a CB₁-mediated reduction in singing (101). Thus, the endocannabinoid system may have a fundamental role in linking behavioural activity with food availability.

1
2 The endocannabinoid signalling system is also involved in mechanisms of learning and
3 memory and studies on rodent models have, for example, provided evidence of roles in mechanisms
4 of synaptic plasticity in brain regions critical for declarative memory (hippocampus) and in neural
5 mechanisms underlying extinction of aversive memories (102). In this aspect of endocannabinoid
6 signalling, research on a non-mammalian vertebrate, the zebra finch *Taeniopygia guttata*, has been
7 particularly significant. The zebra finch is an attractive model system for research on neural
8 mechanisms of learning because, in a manner analogous to human language acquisition, male zebra
9 finches learn a song pattern during juvenile development (103). Ken Soderstrom and colleagues have
10 found that cannabinoid exposure during sensorimotor stages of vocal development alters song
11 patterns produced later during adulthood (104) with distinct sub-periods of sensitivity (105).
12 Consistent with these findings, the CB₁ receptor is expressed in brain regions involved in song
13 learning (89) and song production (106), with cannabinoid exposure during sensorimotor stages of
14 vocal development leading to alterations in CB₁ expression and 2-AG levels in the adult brain (107).
15 Further investigation of mechanisms of action have revealed that cannabinoid exposure during
16 sensorimotor stages of vocal development leads to increased basal expression of the transcription
17 factor FoxP2 in the striatum of adult birds, including the area X song region (108) and increased
18 dendritic spine densities (109).

19
20 Analysis of the effects of cannabinoids on adult zebra finches reveals an inhibitory effect on
21 song production (110) and an associated inhibition of expression of the transcription factor ZENK in
22 a brain region that is involved in auditory perception (the caudomedial neostriatum) (111). Adult
23 exposure to cannabinoids also causes dose-related inhibitory or stimulatory effects on neuronal
24 activity (based on c-fos expression) in brain regions that control vocal motor output (112).

25
26 Thus far, the zebra finch cannabinoid studies have focused primarily on the effects of
27 exogenous cannabinoids (in particular WIN 55,212-2) on song learning and song production. This
28 has provided insights on how developmental exposure to cannabinoids can lead to permanent
29 alterations in brain function and behaviour, which may be highly relevant to an understanding of the

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 risks associated with cannabis use in adolescents (113). With the recent development of drugs that
3
4 selectively inhibit degradation of endocannabinoids (e.g. the MAGL inhibitor JZL184 and the
5
6 FAAH inhibitor PF-3845), it may now be possible to obtain more insights on the physiological roles
7
8 of the endocannabinoid signalling system in learning using the zebra finch as a model system.
9

10
11
12
13 **(b) Neurobiology of CB₁/CB₂-type endocannabinoid signalling in invertebrate chordates**
14

15 As highlighted above, the discovery of genes encoding co-orthologs of CB₁ and CB₂ in the
16 urochordate *Ciona intestinalis* (CiCBR) (77) and in the cephalochordate *Branchiostoma floridae*
17 (BfCBR) (76) revealed that the evolutionary origin of CB₁/CB₂-type cannabinoid receptors could be
18 traced back beyond the vertebrates to the common ancestor of extant chordates. As of yet the
19 pharmacological properties of CiCBR and BfCBR have not been determined and although these
20 receptors are clearly CB₁/CB₂-type receptors based on sequence similarity, it should not be assumed
21 that CiCBR and BfCBR are necessarily activated by the endocannabinoids 2-AG and anandamide *in*
22 *vivo*. The G-protein coupled receptors in mammals that are most closely related CB₁ and CB₂ are
23 activated by other lipid signalling molecules – the lysophospholipids (114). Therefore, whilst we
24 cannot assume that CiCBR and BfCBR are activated by the endocannabinoids 2-AG and
25 anandamide, it seems reasonable to assume that these receptors are activated *in vivo* by
26 endocannabinoid/lysophospholipid-like lipid signalling molecules. Thus, determining the identity of
27 endogenous ligands for CiCBR and BfCBR is of great interest because it may shed light on how and
28 when CB₁/CB₂-type receptors acquired their property of binding 2-AG and anandamide.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Although the pharmacological properties of CiCBR and BfCBR are unknown, some insights
47 into the physiological roles of CiCBR have been obtained by investigation of the distribution CiCBR
48 expression in *Ciona intestinalis* using specific antibodies that bind to the C-terminal tail of the
49 receptor. These immunocytochemical studies revealed that the ~46 kDa CiCBR protein is
50 concentrated in the cerebral ganglion of *Ciona*, which is located between the inhalent and exhalent
51 siphons that confer on this species and other sea squirts a filter-feeding lifestyle. Furthermore,
52
53
54
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CiCBR-immunoreactivity is localised in a dense meshwork of neuronal processes in the neuropile of the cerebral ganglion. CiCBR-immunoreactivity is also present in the axons and axon terminals of neurons that project via peripheral nerves over and around the internal surfaces of the inhalent and exhalent siphons (115), a pattern of expression consistent with behavioural effects of cannabinoids on siphon activity in *Ciona* (116).

The axonal targeting of CiCBR in *Ciona* is intriguing because of its similarity to CB₁ receptor localisation in mammalian CB₁-expressing neurons. It suggests that CiCBR may have a similar role to CB₁ receptors by acting as an axonal regulator of neurotransmitter release. Furthermore, it implies that the role of CB₁ receptors as presynaptic regulators of neurotransmitter release may be very ancient, preceding the gene duplication that gave rise to CB₁ and CB₂ receptors and dating back at least as far as the common ancestor of vertebrates and urochordates. What isn't yet known is the molecular identity of neurotransmitter(s) or neurohormone(s) that are released by CiCBR-expressing neurons in *Ciona*. Is CiCBR expressed in GABAergic and/or glutamatergic neurons, as in mammals, or is CiCBR expressed in other types of neurons such as aminergic or peptidergic neurons? These are questions that need to be addressed if we are to gain an understanding of the physiological roles of CiCBR in *Ciona*. It would also be interesting to determine if BfCBR is expressed by neurons and targeted to axon terminals in *Branchiostoma floridae*. If it is, then this would indicate that the axonal targeting of CB₁-type receptors that is seen in vertebrates can be traced back to the common ancestor of all extant chordates.

It is important to note that because CiCBR and BfCBR are co-orthologs of CB₁-type and CB₂-type cannabinoid receptors, then these receptors in invertebrate chordates may have both CB₁-like and CB₂-like functional properties. It is of interest, therefore, that CiCBR is not only expressed in neurons but is also present in hemocytes in *Ciona* (117), which may be indicative of an ancient CB₂-like role in regulation of immunological processes. Thus, we can imagine a scenario where in the invertebrate chordate ancestor of vertebrates a CiCBR/BfCBR-like protein may have had both CB₁-type and CB₂-type functions and following duplication of the gene encoding a CiCBR/BfCBR-

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 like protein the duplicated receptors diverged and acquired their more specific CB₁-type and CB₂-
3 type functions. Clearly this is speculative but it provides a rationale for further investigation of the
4 physiological roles of CiCBR and BfCBR and the physiological roles of CB₁-type and CB₂-type
5 cannabinoid receptors in non-mammalian vertebrates.
6
7
8
9

10
11
12
13 ***(c) Neurobiology of non-CB₁/CB₂ mediated endocannabinoid signalling in invertebrates***
14

15
16
17
18 Whilst CB₁/CB₂-type receptors do not occur in the majority of invertebrates, as highlighted
19 above, the biochemical pathways for biosynthesis/inactivation of 2-AG and anandamide occur
20 throughout the animal kingdom. Therefore, it is of interest to review evidence of non-CB₁/CB₂
21 mediated endocannabinoid signalling in the nervous systems of invertebrates.
22
23
24
25
26
27

28
29 ***(i) Non-chordate deuterostomes - echinoderms and hemichordates***
30

31 Effects of cannabinoids and endocannabinoids on fertilisation in the sea urchin
32
33 *Strongylocentrotus purpuratus* (118) and the occurrence of an endocannabinoid-like signalling
34 system in embryonic and larval sea urchins (Buznikov et al. 2010) have been reported. Furthermore,
35 opportunities to investigate the existence and functions of endocannabinoid-like signalling systems
36 in echinoderms and hemichordates have been facilitated recently by sequencing of the
37 transcriptomes/genomes of the sea urchin *Strongylocentrotus purpuratus* and the hemichordate
38 *Saccoglossus kowalevskii* (119-121).
39
40
41
42
43
44
45
46
47
48

49 ***(ii) Lophotrochozoan protostomian invertebrates – annelids***
50

51 Investigation of a putative endocannabinoid-like signalling system in annelids has largely
52 focussed on the medicinal leech *Hirudo medicinalis*, which is a well-established model system in
53 neurobiology. In 1997, Stefano *et al.* reported the sequence of a putative leech cDNA encoding a
54 partial (153 amino-acids) protein sequence sharing significant similarity with mammalian CB₁
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

cannabinoid receptors (122). However, subsequent analysis of the sequence revealed that it was chimeric, with a central region sharing 98% identity with the bovine adrenocorticotrophic hormone (ACTH) receptor and outer regions sharing 65-68% identity with mammalian CB₁ receptors (123). Horizontal transfer of bovine DNA to leeches that feed on bovine blood was offered as a possible explanation for this unusual sequence (123) but perhaps a more likely explanation is that the sequence is an artefact (1). More recently, the genome of the leech *Hellobdella robusta* has been sequenced (<http://genome.jgi-psf.org/Helro1>) and analysis of the genomic sequence data does not reveal the presence of any CB₁-like genes, consistent with analysis of genomic sequence data from other protostomian invertebrates. However, there is evidence that an endocannabinoid-like system may exist in leeches and other annelids.

Detection of binding sites for ³H-anandamide in cell membranes derived from the CNS of *Hirudo medicinalis* suggested the presence of putative receptors for this molecule (122), whilst binding sites for the cannabinoid ³H-CP55,940 have been detected in the nervous system of another annelid species, the earthworm *Lumbricus terrestris* (79). Moreover, the detection of both anandamide and 2-AG and associated enzymatic activities in extracts of leech ganglia indicates that the biosynthetic machinery for synthesis of these molecules exists in annelids (124).

Building upon these biochemical studies are a recent series of papers by Brian Burrell and colleagues that have provided evidence that an endocannabinoid signalling system modulates synaptic transmission in the leech *Hirudo medicinalis*. Li and Burrell found that in the polysynaptic pathway from touch-sensitive mechanosensory neurons (T) to S interneurons in *Hirudo*, long-term depression (LTD) of synaptic transmission is observed following low frequency electrical stimulation (1 Hz) for 450 s or 900 s. LTD elicited by 450 s low frequency stimulation was blocked by NMDA receptor antagonists but LTD elicited by 900 s low frequency stimulation was unaffected by NMDA receptor antagonists. Interestingly, LTD elicited by 900 s low frequency stimulation was blocked by the cannabinoid receptor antagonist AM251 and by the DAG lipase inhibitor RHC80267, suggesting the involvement of an endocannabinoid-like signalling mechanism in this particular form

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 of synaptic plasticity. Importantly, application of 2-AG or the cannabinoid receptor agonist CP-
3
4 55,940 induced LTD of the T-S synaptic pathway, providing further evidence of an
5
6 endocannabinoid-like mechanism of synaptic plasticity in the leech (125).
7
8

9 Further characterisation of this system has revealed that LTD elicited by 900 s low frequency
10 stimulation requires activation of metabotropic serotonin receptors and is dependent on Ca^{2+}
11 elevation in the S interneuron, mediated by voltage-gated Ca^{2+} channels and intracellular inositol
12 triphosphate receptors. Furthermore, this particular form of LTD also involves stimulation of nitric
13 oxide synthase and a decrease in cAMP signalling (126). However, because synaptic plasticity is
14 being examined here in the context of a polysynaptic pathway, mechanistic interpretation of these
15 findings is complicated. Nevertheless, given that CB_1/CB_2 -type cannabinoid receptors do not exist in
16 annelids and other protostomian invertebrates, these findings raise intriguing questions concerning
17 the molecular nature of the putative receptors that mediate effects of endogenous or exogenous 2-AG
18 (and other related lipids) in the nervous system of the leech.
19
20
21
22
23
24
25
26
27
28
29
30

31 Research on mammalian models has provided evidence that transient receptor potential
32 vanilloid (TRPV)-type receptors are activated by endocannabinoids *in vitro* and mediate *in vivo*
33 effects of endocannabinoids (72, 127). Thus, Burrell and colleagues have investigated TRPV-type
34 receptors as potential mediators of endocannabinoid-dependent LTD in the leech nervous system. In
35 the leech there are three types of cutaneous mechanosensory neurons: low threshold touch (T),
36 moderate threshold pressure (P) and high threshold nociceptive (N) neurons, all of which synapse
37 onto the longitudinal motor neuron (L cell), which controls contraction during whole-body
38 shortening. Low-frequency stimulation of the T neurons induces heterosynaptic LTD of
39 glutamatergic transmission at the N-to-L synapse and, importantly, Yuan and Burrell found that this
40 was blocked by DAG lipase inhibitors and the TRPV antagonists capsazepine and SB 366791.
41
42 Furthermore, application of 2-AG and the TRPV agonist capsaicin mimicked LTD at the N-to-L
43 synapses and these effects of 2-AG and capsaicin were blocked by capsazepine. Pre-treatment with
44 2-AG or capsaicin occluded subsequent expression of LTD induced by low-frequency stimulation.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Finally, presynaptic, but not postsynaptic, intracellular injection of capsazepine blocked both low-frequency stimulation-induced and 2-AG-induced LTD, indicating that presynaptic TRPV-type receptors mediate LTD at the N-to-L synapse. Collectively, these findings indicate that low-frequency stimulation of T neurons stimulates postsynaptic synthesis of 2-AG or a 2-AG-like molecule in L neurons, which then acts in a retrograde manner to inhibit heterosynaptic neurotransmitter release by N neurons via a TRPV-type receptor mediated mechanism (128).

Evidence that presynaptic TRPV-type receptor mediated LTD may be a widespread mechanism of synaptic plasticity in the leech nervous system has been obtained in a subsequent study using the leech T-S synaptic pathway as a model preparation (129). LTD is induced when a spike train is triggered in the S cell 1-10 s prior to stimulation of the T cell and this is blocked by perfusion of the preparation with the cannabinoid receptor antagonist AM251 or the DAG lipase inhibitor RHC80267 and by injection of the DAG lipase inhibitor tetrahydrolipstatin into the S cell. Perfusion with the TRPV antagonist capsazepine also blocked LTD induced by a spike train in the S cell 1-10 s prior to stimulation of the T cell. This effect of capsazepine was observed when it was injected into the T cell but not when it was injected into the S cell. Thus, it appears that mechanisms of LTD involving postsynaptic synthesis of 2-AG or 2-AG-like molecules by DAG lipase and presynaptic activation of TRPV-type receptors occur widely in the leech nervous system. These findings raise interest in determination of the molecular identity of the putative TRPV-type receptors that mediate LTD in the leech nervous system. This would enable investigation of the cellular distribution of these receptors in the leech nervous system and comparison of their molecular properties with mammalian TRPV receptors. Likewise, it would be interesting to investigate the expression of DAG lipases in the leech nervous system at a cellular and sub-cellular level to assess DAG lipases as potential sources of 2-AG or 2-AG-like molecules that mediate LTD via retrograde synaptic signalling mechanisms.

The discovery of LTD mediated by 2-AG or 2-AG-like molecules and TRPV-type receptors in the leech nervous system suggest that endocannabinoid-mediated retrograde synaptic signalling is

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

an evolutionarily ancient mechanism that predates the origins of CB₁/CB₂-type cannabinoid receptors in chordates. If this is correct, these mechanisms of synaptic plasticity may also operate in the nervous systems of other invertebrates (see below). Thus, the findings of Burrell and colleagues have paved the way for further investigation of the function of endocannabinoid-type signalling mechanisms in the nervous systems of all animals, extending the scope for research on the comparative neurobiology of endocannabinoid signalling well beyond the phylum Chordata.

(iii) *Lophotrochozoan protostomian invertebrates – molluscs*

There has been relatively little investigation of endocannabinoid-like signalling systems in molluscs. This is perhaps surprising given the importance of molluscs as model systems in neurobiology, in particular the gastropod species *Aplysia californica* and *Lymnaea stagnalis* (130). The discovery that an endocannabinoid-type signalling system mediates synaptic plasticity in the leech *Hirudo medicinalis*, as highlighted above, may act as a stimulus for researchers to investigate if similar mechanisms operate in molluscan species.

Importantly, biochemical studies on bivalve molluscan species have revealed the presence of *N*-acylethanolamines, including anandamide, putative binding sites for anandamide and a FAAH-like enzymatic activity (131, 132). Furthermore, transcriptomic/genomic sequence data are available for molluscan species, including the gastropod *Aplysia californica* (133) and the bivalve *Crassostrea gigas* (134). Therefore, identification of genes encoding proteins implicated in endocannabinoid signalling (e.g. DAG lipases, MAGL, NAPE-PLD, FAAH) is now feasible for molluscan species, which will facilitate detailed investigation of endocannabinoid-like signalling systems in molluscan species.

(iv) *Ecdysozoan protostomian invertebrates – nematodes*

The nematode *Caenorhabditis elegans* was the first animal species to have its genome sequenced and analysis of this sequence provided the first evidence that CB₁/CB₂-type cannabinoid

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

receptors do not occur throughout animal kingdom (1). A gene encoding a G-protein coupled receptor (C02H7.2) that shares sequence similarity with CB₁/CB₂-type cannabinoid receptors is present in *Caenorhabditis elegans*, but analysis of its sequence indicates that it is not an ortholog (1, 78). Nevertheless, binding sites for the cannabinoid ³H-CP-55,940 have been detected in the nematode *Panagrellus redivivus*, suggesting the presence of other non-CB₁/CB₂-type cannabinoid receptors in nematodes (79)

The presence of the endocannabinoids anandamide and 2-AG has been specifically investigated in nematodes by analysis of three species, *Caenorhabditis elegans*, *Caenorhabditis briggsae* and *Pelodera strongyloides* and both anandamide and 2-AG were detected in all three species. However, anandamide and 2-AG were not detected in a mutant strain of *Caenorhabditis elegans* (*fat-3*) that lacks functional activity of the delta-6 desaturase enzyme required for synthesis of long chain polyunsaturated fatty acids (including arachidonic acid) (135).

Importantly, the physiological roles of anandamide and other *N*-acylethanolamines (NAEs) in *C. elegans* have recently been investigated, exploiting the use of techniques to manipulate expression of genes encoding enzymes involved in NAE metabolism. Suppression of FAAH using RNA interference (RNAi) or FAAH inhibitors (URB597) caused an increase in the levels of anandamide and other NAEs and overexpression of the *faah-1* gene caused a decrease in levels of anandamide and other NAEs, demonstrating the importance of FAAH as a regulator NAEs in an invertebrate species (136). Furthermore, *faah-1* overexpression caused a developmental delay that was rescued by *faah-1* RNAi, indicating a role for NAEs in promotion of larval development in *C. elegans*. Peak levels of NAEs are detected during the second larval stage (L2) at which time animals are committed to reproductive growth, but NAE levels are reduced at L2 in animals committed to an alternative diapause stage (dauer) induced by dietary restriction. This suggested that NAEs may act as signals of an altered metabolic state and, consistent with this notion, exogenous application of the NAE eicosapentaenoyl ethanolamide (EPEA), and to a lesser extent anandamide, was found to rescue dauer formation. Worms overexpressing *faah-1* also exhibited resistance to thermal stress and

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 increased adult lifespan, whereas application of EPEA caused a reduction in thermotolerance and
3 lifespan, most strikingly in animals under dietary restriction. Collectively, the data reported by
4
5 Lucanic et al. indicate that the effect of dietary restriction on lifespan extension is mediated, at least
6
7 in part, by a reduction in NAE signaling. However, the mechanisms by which NAEs exert effects on
8
9 lifespan in *C. elegans* are as yet unknown and therefore identification of NAE receptors in
10
11 nematodes now represents a fascinating objective for the future.
12
13
14

15
16
17
18 (v) *Ecdysozoan protostomian invertebrates – arthropods*
19

20 Sequencing of the genome of an arthropod species, the insect *Drosophila melanogaster*,
21 provided key evidence that CB₁/CB₂-type cannabinoids receptors do not occur throughout the animal
22 kingdom (1) and this has been supported by sequencing of other arthropod genomes. Nevertheless,
23
24 binding studies using radiolabelled cannabinoids have revealed the presence of putative binding sites
25
26 in a variety of arthropod species (79), although identification of membrane proteins that bind
27
28 cannabinoids has yet to be accomplished for any arthropod species. Evidence that TRPV-type ion
29
30 channels mediate effects of endocannabinoids in the nervous system of the leech *Hirudo medicinalis*
31
32 (128) points to these proteins as potential endocannabinoid receptors in arthropods. It is noteworthy
33
34 that the prototype for the TRP ion channel family was first discovered in *Drosophila* as a result of
35
36 molecular analysis of the *transient receptor potential (trp)* mutant that has a defective
37
38 phototransduction mechanism (137). Interestingly, analysis of phototransduction in *Drosophila* has
39
40 revealed similarities with mechanisms of 2-AG biosynthesis. Thus, the photon-activated rhodopsin
41
42 protein is coupled via G-proteins to stimulate activation of phospholipase C (PLC) and the
43
44 diacylglycerols (DAGs) generated by PLC are substrates for a DAG lipase that is a homolog of the
45
46 mammalian enzymes DAGL α and DAGL β . The *Drosophila* DAG lipase mutant (*inaE*) is defective
47
48 in photoreceptor responses to light and a DAG metabolite is thought to mediate phototransduction by
49
50 activating TRP and/or TRP-like (TRPL) ion channels (138). However, the identity of the DAG
51
52 metabolite that binds to and activates the TRP/TRPL phototransduction channels is not known,
53
54
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

1
2 although there is evidence that it may be a polyunsaturated fatty acid (PUFA) (137). This suggests
3
4 the existence and activity of a MAG lipase in the phototransduction pathway, but one has yet to be
5
6 identified. As highlighted above, *Drosophila* and other insects do not have an ortholog of the MAGL
7
8 enzyme that has such a key role in 2-AG metabolism in mammals. Therefore other as yet
9
10 uncharacterised enzymes may generate endogenous TRP/TRPL ligands from MAG substrates.
11

12
13 Interestingly, DAG lipase is not only expressed in *Drosophila* photoreceptors but is also
14
15 expressed more widely in the brain (138). Therefore, investigation of the physiological roles of DAG
16
17 lipase and its metabolites in the nervous system of *Drosophila* might be fruitful in revealing the
18
19 existence of an endocannabinoid-like signalling system that regulates synaptic activity in insects and
20
21 other arthropods.
22
23

24 25 26 (vi) *Cnidarians*

27
28 Cnidarians are considered to be the most primitive animals with nervous systems and
29
30 evidence of an endocannabinoid-like system in the hydrozoan *Hydra viridis* has been reported (139).
31
32 Sequencing of the genomes *Hydra magnipapillata* and the anthozoan *Nematostella vectensis* (140,
33
34 141) has presented new opportunities for molecular analysis of putative endocannabinoid signalling
35
36 mechanisms in the simple nervous systems of these animals.
37
38
39
40
41
42
43

44 45 5. CONCLUDING COMMENTS

46
47 The value and importance of non-mammalian animals for cannabinoid research has been
48
49 illustrated here with reference to studies on “model organisms” ranging from leeches to lampreys
50
51 and from zebrafish to zebra finches. However, we should not look upon cannabinoid-related studies
52
53 on non-mammalian animals solely from a utilitarian perspective. Research on the evolution and
54
55 comparative neurobiology of endocannabinoid signalling is intrinsically interesting and there is great
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

potential to deepen our understanding of this aspect of nervous system function by revealing “the art of the possible” in the diverse branches of the tree of life.

ACKNOWLEDGEMENTS

I am grateful to Dr Bradley Alger (University of Maryland, USA), Dr Brian Burrell (University of South Dakota, USA) and Dr Michaela Egertová (Queen Mary, University of London, UK) for commenting on and suggesting improvements to the manuscript during its preparation.

References

1. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. *Philos Trans R Soc Lond B Biol Sci.* 2001 Mar 29;356(1407):381-408.
2. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. *Nature.* 2001 Mar 29;410(6828):588-92.
3. Kreitzer AC, Regehr WG. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. *Neuron.* 2001 Mar;29(3):717-27.
4. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. *Neuron.* [Research Support, Non-U.S. Gov't]. 2001 Mar;29(3):729-38.
5. Egertová M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. *Proc Biol Sci.* 1998 Nov 7;265(1410):2081-5.
6. Alger BE. Endocannabinoids at the synapse a decade after the Dies Mirabilis (29 March 2001): what we still do not know. *J Physiol.* 2012 Jan 30.
7. Pertwee RG. Pharmacological actions of cannabinoids. *Handb Exp Pharmacol.* 2005(168):1-51.
8. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol.* 1988 Nov;34(5):605-13.
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature.* 1990 Aug 9;346(6284):561-4.
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature.* 1993 Sep 2;365(6441):61-5.
11. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. *Science.* 1999 Jan 15;283(5400):401-4.
12. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. *Proc Natl Acad Sci U S A.* 1999 May 11;96(10):5780-5.
13. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. *Eur J Pharmacol.* 2000 May 19;396(2-3):141-9.
14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science.* [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1992 Dec 18;258(5090):1946-9.
15. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochemical pharmacology.* [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 1995 Jun 29;50(1):83-90.
16. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun.* 1995 Oct 4;215(1):89-97.
17. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol.* 2003 Nov 10;163(3):463-8.
18. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, et al. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. *Journal of neuroscience.* [Research Support, Non-U.S. Gov't]. 2010 Feb 10;30(6):2017-24.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, et al. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. *Neuron*. [In Vitro Research Support, Non-U.S. Gov't]. 2010 Feb 11;65(3):320-7.
20. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proceedings of the National Academy of Sciences of the United States of America*. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 2002 Aug 6;99(16):10819-24.
21. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. *Nature neuroscience*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2010 Sep;13(9):1113-9.
22. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2009 Jan;5(1):37-44.
23. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. *Chem Biol*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2007 Dec;14(12):1347-56.
24. Schmid HH. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? *Chem Phys Lipids*. 2000 Nov;108(1-2):71-87.
25. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. *J Neurosci*. 1996 Jun 15;16(12):3934-42.
26. Schmid HH, Schmid PC, Natarajan V. N-acylated glycerophospholipids and their derivatives. *Prog Lipid Res*. 1990;29(1):1-43.
27. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. *The Journal of biological chemistry*. [Research Support, Non-U.S. Gov't]. 2004 Feb 13;279(7):5298-305.
28. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. *Biochemistry*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2006 Apr 18;45(15):4720-6.
29. Egertová M, Simon GM, Cravatt BF, Elphick MR. Localization of N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) expression in mouse brain: A new perspective on N-acylethanolamines as neural signaling molecules. *The Journal of comparative neurology*. [Research Support, Non-U.S. Gov't]. 2008 Feb 1;506(4):604-15.
30. Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. *The Journal of biological chemistry*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2008 Apr 4;283(14):9341-9.
31. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. *The Journal of biological chemistry*. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2006 Sep 8;281(36):26465-72.
32. Simon GM, Cravatt BF. Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. *Mol Biosyst*. 2010 Aug;6(8):1411-8.
33. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, Luquet S, et al. Multiple pathways involved in the biosynthesis of anandamide. *Neuropharmacology*. [Research Support, N.I.H., Intramural]. 2008 Jan;54(1):1-7.

- 1
2
3 34. Okamoto Y, Tsuboi K, Ueda N. Enzymatic formation of anandamide. *Vitam Horm.*
4 [Review]. 2009;81:1-24.
5 35. Tsuboi K, Okamoto Y, Ikematsu N, Inoue M, Shimizu Y, Uyama T, et al. Enzymatic
6 formation of N-acylethanolamines from N-acylethanolamine plasmalogen through N-
7 acylphosphatidylethanolamine-hydrolyzing phospholipase D-dependent and -independent pathways.
8 *Biochimica et biophysica acta.* [Research Support, N.I.H., Extramural
9 Research Support, Non-U.S. Gov't]. 2011 Oct;1811(10):565-77.
10 36. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular
11 characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature.* 1996 Nov
12 7;384(6604):83-7.
13 37. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al.
14 Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking
15 fatty acid amide hydrolase. *Proc Natl Acad Sci U S A.* 2001 Jul 31;98(16):9371-6.
16 38. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. Discovery and
17 characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. *Chem Biol.*
18 [Research Support, N.I.H., Extramural
19 Research Support, Non-U.S. Gov't]. 2009 Apr 24;16(4):411-20.
20 39. Wei BQ, Mikkelsen TS, McKinney MK, Lander ES, Cravatt BF. A second fatty acid amide
21 hydrolase with variable distribution among placental mammals. *The Journal of biological chemistry.*
22 [Research Support, N.I.H., Extramural
23 Research Support, Non-U.S. Gov't]. 2006 Dec 1;281(48):36569-78.
24 40. Kaczocha M, Glaser ST, Chae J, Brown DA, Deutsch DG. Lipid droplets are novel sites of
25 N-acylethanolamine inactivation by fatty acid amide hydrolase-2. *The Journal of biological*
26 *chemistry.* [Research Support, N.I.H., Extramural]. 2010 Jan 22;285(4):2796-806.
27 41. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide
28 by cyclooxygenase-2. *The Journal of biological chemistry.* 1997 Aug 22;272(34):21181-6.
29 42. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid
30 effects in hippocampus. *Nature neuroscience.* [Comparative Study
31 In Vitro
32 Research Support, U.S. Gov't, P.H.S.]. 2004 Jul;7(7):697-8.
33 43. Piomelli D, Beltramo M, Glasnapp S, Lin SY, Goutopoulos A, Xie XQ, et al. Structural
34 determinants for recognition and translocation by the anandamide transporter. *Proceedings of the*
35 *National Academy of Sciences of the United States of America.* [Research Support, Non-U.S. Gov't
36 Research Support, U.S. Gov't, P.H.S.]. 1999 May 11;96(10):5802-7.
37 44. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence
38 against the presence of an anandamide transporter. *Proceedings of the National Academy of*
39 *Sciences of the United States of America.* [Research Support, U.S. Gov't, P.H.S.]. 2003 Apr
40 1;100(7):4269-74.
41 45. Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, et al. A catalytically silent
42 FAAH-1 variant drives anandamide transport in neurons. *Nature neuroscience.* [Research Support,
43 N.I.H., Extramural
44 Research Support, Non-U.S. Gov't]. 2012 Jan;15(1):64-9.
45 46. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and
46 arrestins. *Annu Rev Physiol.* [Research Support, N.I.H., Extramural
47 Research Support, Non-U.S. Gov't
48 Review]. 2007;69:511-34.
49 47. Metherell LA, Chapple JP, Cooray S, David A, Becker C, Ruschendorf F, et al. Mutations in
50 MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid
51 deficiency type 2. *Nat Genet.* [Research Support, Non-U.S. Gov't]. 2005 Feb;37(2):166-70.
52 48. Cooray SN, Almiro Do Vale I, Leung KY, Webb TR, Chapple JP, Egertová M, et al. The
53 melanocortin 2 receptor accessory protein exists as a homodimer and is essential for the function of
54
55
56
57
58
59
60

- 1
2 the melanocortin 2 receptor in the mouse y1 cell line. *Endocrinology*. [Research Support, Non-U.S.
3 Gov't]. 2008 Apr;149(4):1935-41.
- 4 49. Chan LF, Webb TR, Chung TT, Meimaridou E, Cooray SN, Guasti L, et al. MRAP and
5 MRAP2 are bidirectional regulators of the melanocortin receptor family. *Proceedings of the National*
6 *Academy of Sciences of the United States of America*. [Research Support, Non-U.S. Gov't]. 2009
7 Apr 14;106(15):6146-51.
- 8 50. Niehaus JL, Liu Y, Wallis KT, Egertová M, Bhartur SG, Mukhopadhyay S, et al. CB1
9 cannabinoid receptor activity is modulated by the cannabinoid receptor interacting protein CRIP 1a.
10 *Molecular pharmacology*. [Comparative Study
11 Research Support, N.I.H., Extramural
12 Research Support, Non-U.S. Gov't]. 2007 Dec;72(6):1557-66.
- 13 51. Nie J, Lewis DL. Structural domains of the CB1 cannabinoid receptor that contribute to
14 constitutive activity and G-protein sequestration. *Journal of neuroscience*. [Research Support, U.S.
15 Gov't, P.H.S.]. 2001 Nov 15;21(22):8758-64.
- 16 52. Stauffer B, Wallis KT, Wilson SP, Egertová M, Elphick MR, Lewis DL, et al. CRIP1a
17 switches cannabinoid receptor agonist/antagonist-mediated protection from glutamate excitotoxicity.
18 *Neuroscience letters*. [Research Support, Non-U.S. Gov't]. 2011 Oct 10;503(3):224-8.
- 19 53. Egertova M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid
20 signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat
21 brain. *Proceedings Biological sciences / The Royal Society*. [Research Support, Non-U.S. Gov't
22 Research Support, U.S. Gov't, P.H.S.]. 1998 Nov 7;265(1410):2081-5.
- 23 54. Piomelli D, Beltramo M, Giuffrida A, Stella N. Endogenous cannabinoid signaling.
24 *Neurobiol Dis*. [Research Support, Non-U.S. Gov't
25 Research Support, U.S. Gov't, P.H.S.
26 Review]. 1998 Dec;5(6 Pt B):462-73.
- 27 55. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid
28 receptors in the basal ganglia of the rat. *Brain research*. 1991 May 3;547(2):267-74.
- 29 56. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization
30 and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.
31 *Journal of neuroscience*. 1991 Feb;11(2):563-83.
- 32 57. Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain.
33 *J Comp Neurol*. 1993 Jan 22;327(4):535-50.
- 34 58. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat
35 brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.
36 *Neuroscience*. [Comparative Study
37 Research Support, Non-U.S. Gov't]. 1992;48(3):655-68.
- 38 59. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical
39 distribution of cannabinoid CB1 receptors in the rat central nervous system. *Neuroscience*. [Research
40 Support, Non-U.S. Gov't
41 Research Support, U.S. Gov't, P.H.S.]. 1998 Mar;83(2):393-411.
- 42 60. Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA. Immunohistochemical
43 localization of the neural cannabinoid receptor in rat brain. *J Neurosci Res*. [Research Support, U.S.
44 Gov't, P.H.S.]. 1998 Feb 1;51(3):391-402.
- 45 61. Roth SH. Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on
46 cholinergic transmission in the myenteric plexus of the guinea pig. *Canadian journal of physiology*
47 *and pharmacology*. [In Vitro]. 1978 Dec;56(6):968-75.
- 48 62. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-
49 term potentiation. *Nature*. [In Vitro
50 Research Support, Non-U.S. Gov't
51 Research Support, U.S. Gov't, P.H.S.]. 1997 Aug 21;388(6644):773-8.
- 52 63. Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, et al. Localization of
53 diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production
54
55
56
57
58
59
60

- 1
2 site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. The
3 Journal of neuroscience : the official journal of the Society for Neuroscience. [Comparative Study
4 Research Support, Non-U.S. Gov't]. 2006 May 3;26(18):4740-51.
5
6 64. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, et al. Segregation of two
7 endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat
8 hippocampus, cerebellum and amygdala. The European journal of neuroscience. [Comparative Study
9 Research Support, Non-U.S. Gov't
10 Research Support, U.S. Gov't, P.H.S.]. 2004 Jul;20(2):441-58.
11 65. Pan B, Wang W, Zhong P, Blankman JL, Cravatt BF, Liu QS. Alterations of
12 endocannabinoid signaling, synaptic plasticity, learning, and memory in monoacylglycerol lipase
13 knock-out mice. The Journal of neuroscience : the official journal of the Society for Neuroscience.
14 [Research Support, N.I.H., Extramural
15 Research Support, Non-U.S. Gov't]. 2011 Sep 21;31(38):13420-30.
16 66. Zhong P, Pan B, Gao XP, Blankman JL, Cravatt BF, Liu QS. Genetic deletion of
17 monoacylglycerol lipase alters endocannabinoid-mediated retrograde synaptic depression in the
18 cerebellum. J Physiol. [In Vitro
19 Research Support, N.I.H., Extramural
20 Research Support, Non-U.S. Gov't]. 2011 Oct 15;589(Pt 20):4847-55.
21 67. Pan B, Wang W, Long JZ, Sun D, Hillard CJ, Cravatt BF, et al. Blockade of 2-
22 arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-
23 (dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances
24 retrograde endocannabinoid signaling. The Journal of pharmacology and experimental therapeutics.
25 [Research Support, N.I.H., Extramural
26 Research Support, Non-U.S. Gov't]. 2009 Nov;331(2):591-7.
27 68. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to
28 long-term depression in the striatum. Nature neuroscience. [In Vitro
29 Research Support, U.S. Gov't, P.H.S.]. 2002 May;5(5):446-51.
30 69. Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, Manzoni OJ. Molecular
31 components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS One.
32 [Research Support, Non-U.S. Gov't]. 2007;2(8):e709.
33 70. Grueter BA, Brasnjo G, Malenka RC. Postsynaptic TRPV1 triggers cell type-specific long-
34 term depression in the nucleus accumbens. Nature neuroscience. [Comparative Study
35 Research Support, N.I.H., Extramural]. 2010 Dec;13(12):1519-25.
36 71. Kim J, Alger BE. Reduction in endocannabinoid tone is a homeostatic mechanism for
37 specific inhibitory synapses. Nature neuroscience. [In Vitro
38 Research Support, N.I.H., Extramural]. 2010 May;13(5):592-600.
39 72. Chavez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers
40 postsynaptic long-term depression in dentate gyrus. Nature neuroscience. [Comparative Study
41 Research Support, N.I.H., Extramural]. 2010 Dec;13(12):1511-8.
42 73. Onaivi ES. Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS. Curr
43 Neuropharmacol. 2011 Mar;9(1):205-8.
44 74. Elphick MR, Egertová M. Cannabinoid Receptor Genetics and Evolution
45 The Cannabinoid Receptors. In: Reggio PH, editor.: Humana Press; 2009. p. 123-49.
46 75. Elphick MR, Egertová M. The phylogenetic distribution and evolutionary origins of
47 endocannabinoid signalling. Handb Exp Pharmacol. 2005(168):283-97.
48 76. Elphick MR. BfCBR: a cannabinoid receptor ortholog in the cephalochordate *Branchiostoma*
49 *floridae* (Amphioxus). Gene. 2007 Sep 1;399(1):65-71.
50 77. Elphick MR, Satou Y, Satoh N. The invertebrate ancestry of endocannabinoid signalling: an
51 orthologue of vertebrate cannabinoid receptors in the urochordate *Ciona intestinalis*. Gene. 2003 Jan
52 2;302(1-2):95-101.
53 78. McPartland JM, Glass M. Functional mapping of cannabinoid receptor homologs in
54 mammals, other vertebrates, and invertebrates. Gene. 2003 Jul 17;312:297-303.
55
56
57
58
59
60

- 1
2
3 79. McPartland JM, Agraval J, Gleeson D, Heasman K, Glass M. Cannabinoid receptors in
4 invertebrates. *J Evol Biol.* 2006 Mar;19(2):366-73.
5 80. Karlsson M, Contreras JA, Hellman U, Tornqvist H, Holm C. cDNA cloning, tissue
6 distribution, and identification of the catalytic triad of monoglyceride lipase. *Evolutionary*
7 *relationship to esterases, lysophospholipases, and haloperoxidases. The Journal of biological*
8 *chemistry.* [Research Support, Non-U.S. Gov't]. 1997 Oct 24;272(43):27218-23.
9 81. Hughes AL, Irausquin S, Friedman R. The evolutionary biology of poxviruses. *Infect Genet*
10 *Evol.* [Research Support, N.I.H., Extramural
11 Review]. 2010 Jan;10(1):50-9.
12 82. Song J, Kyriakatos A, El Manira A. Gating the polarity of endocannabinoid-mediated
13 synaptic plasticity by nitric oxide in the spinal locomotor network. *The Journal of neuroscience : the*
14 *official journal of the Society for Neuroscience.* 2012 Apr 11;32(15):5097-105.
15 83. Thorn Perez C, Hill RH, El Manira A, Grillner S. Endocannabinoids mediate tachykinin-
16 induced effects in the lamprey locomotor network. *Journal of neurophysiology.* [In Vitro
17 Research Support, Non-U.S. Gov't]. 2009 Sep;102(3):1358-65.
18 84. Kyriakatos A, El Manira A. Long-term plasticity of the spinal locomotor circuitry mediated
19 by endocannabinoid and nitric oxide signaling. *The Journal of neuroscience : the official journal of*
20 *the Society for Neuroscience.* [Research Support, Non-U.S. Gov't]. 2007 Nov 14;27(46):12664-74.
21 85. Kettunen P, Kyriakatos A, Hallen K, El Manira A. Neuromodulation via conditional release
22 of endocannabinoids in the spinal locomotor network. *Neuron.* [Research Support, Non-U.S. Gov't].
23 2005 Jan 6;45(1):95-104.
24 86. Cottone E, Forno S, Campantico E, Guastalla A, Viltono L, Mackie K, et al. Expression and
25 distribution of CB1 cannabinoid receptors in the central nervous system of the African cichlid fish
26 *Pelvicachromis pulcher.* *J Comp Neurol.* 2005b May 16;485(4):293-303.
27 87. Cesa R, Mackie K, Beltramo M, Franzoni MF. Cannabinoid receptor CB1-like and glutamic
28 acid decarboxylase-like immunoreactivities in the brain of *Xenopus laevis.* *Cell Tissue Res.* 2001
29 Dec;306(3):391-8.
30 88. Salio C, Cottone E, Conrath M, Franzoni MF. CB1 cannabinoid receptors in amphibian
31 spinal cord: relationships with some nociception markers. *J Chem Neuroanat.* 2002 Sep;24(3):153-
32 62.
33 89. Soderstrom K, Tian Q. Developmental pattern of CB1 cannabinoid receptor
34 immunoreactivity in brain regions important to zebra finch (*Taeniopygia guttata*) song learning and
35 control. *The Journal of comparative neurology.* [Research Support, N.I.H., Extramural]. 2006 Jun
36 10;496(5):739-58.
37 90. Lam CS, Rastegar S, Strahle U. Distribution of cannabinoid receptor 1 in the CNS of
38 zebrafish. *Neuroscience.* 2006;138(1):83-95.
39 91. Cottone E, Campantico E, Guastalla A, Aramu S, Polzonetti-Magni AM, Franzoni M. Are
40 the cannabinoids involved in bony fish reproduction? *Ann N Y Acad Sci.* 2005a Apr;1040:273-6.
41 92. Hollis DM, Coddington EJ, Moore FL. Neuroanatomical Distribution of Cannabinoid
42 Receptor Gene Expression in the Brain of the Rough-Skinned Newt, *Taricha granulosa.* *Brain Behav*
43 *Evol.* 2006 Jan 13;67(3):135-49.
44 93. Stincic TL, Hyson RL. Localization of CB1 cannabinoid receptor mRNA in the brain of the
45 chick (*Gallus domesticus*). *Brain research.* [Research Support, N.I.H., Extramural]. 2008 Dec
46 15;1245:61-73.
47 94. Alonso-Ferrero ME, Paniagua MA, Mostany R, Pilar-Cuellar F, Diez-Alarcia R, Pazos A, et
48 al. Cannabinoid system in the budgerigar brain. *Brain research.* [Comparative Study
49 Research Support, Non-U.S. Gov't]. 2006 May 4;1087(1):105-13.
50 95. Egertová M, Elphick MR. Localisation of cannabinoid receptors in the rat brain using
51 antibodies to the intracellular C-terminal tail of CB1. *J Comp Neurol.* 2000 Jun 26;422(2):159-71.
52 96. Sanudo-Pena MC, Romero J, Seale GE, Fernandez-Ruiz JJ, Walker JM. Activational role of
53 cannabinoids on movement. *European journal of pharmacology.* [Research Support, U.S. Gov't,
54 P.H.S.]. 2000 Mar 17;391(3):269-74.
55
56
57
58
59
60

- 1
2
3 97. Valenti M, Cottone E, Martinez R, De Pedro N, Rubio M, Viveros MP, et al. The
4 endocannabinoid system in the brain of *Carassius auratus* and its possible role in the control of food
5 intake. *J Neurochem*. 2005 Nov;95(3):662-72.
- 6 98. Soderstrom K, Leid M, Moore FL, Murray TF. Behavioral, pharmacological, and molecular
7 characterization of an amphibian cannabinoid receptor. *Journal of neurochemistry*. 2000
8 Jul;75(1):413-23.
- 9 99. Soderstrom K, Johnson F. Zebra finch CB1 cannabinoid receptor: pharmacology and in vivo
10 and in vitro effects of activation. *J Pharmacol Exp Ther*. 2001 Apr;297(1):189-97.
- 11 100. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. *Nature*
12 *neuroscience*. [Review]. 2005 May;8(5):585-9.
- 13 101. Soderstrom K, Tian Q, Valenti M, Di Marzo V. Endocannabinoids link feeding state and
14 auditory perception-related gene expression. *The Journal of neuroscience : the official journal of the*
15 *Society for Neuroscience*. [Research Support, N.I.H., Extramural
16 Research Support, U.S. Gov't, P.H.S.]. 2004 Nov 3;24(44):10013-21.
- 17 102. Marsicano G, Lafenetre P. Roles of the endocannabinoid system in learning and memory.
18 *Curr Top Behav Neurosci*. [Review]. 2009;1:201-30.
- 19 103. Clayton DF. Role of gene regulation in song circuit development and song learning. *Journal*
20 *of neurobiology*. [Research Support, Non-U.S. Gov't
21 Research Support, U.S. Gov't, P.H.S.
22 Review]. 1997 Nov;33(5):549-71.
- 23 104. Soderstrom K, Johnson F. Cannabinoid exposure alters learning of zebra finch vocal patterns.
24 *Brain research Developmental brain research*. [Research Support, U.S. Gov't, P.H.S.]. 2003 May
25 14;142(2):215-7.
- 26 105. Soderstrom K, Tian Q. Distinct periods of cannabinoid sensitivity during zebra finch vocal
27 development. *Brain research Developmental brain research*. [Research Support, U.S. Gov't, P.H.S.].
28 2004 Nov 25;153(2):225-32.
- 29 106. Soderstrom K, Johnson F. CB1 cannabinoid receptor expression in brain regions associated
30 with zebra finch song control. *Brain research*. [Research Support, U.S. Gov't, P.H.S.]. 2000 Feb
31 28;857(1-2):151-7.
- 32 107. Soderstrom K, Poklis JL, Lichtman AH. Cannabinoid exposure during zebra finch
33 sensorimotor vocal learning persistently alters expression of endocannabinoid signaling elements
34 and acute agonist responsiveness. *BMC Neurosci*. [Comparative Study
35 Research Support, N.I.H., Extramural]. 2011;12:3.
- 36 108. Soderstrom K, Luo B. Late-postnatal cannabinoid exposure persistently increases FoxP2
37 expression within zebra finch striatum. *Dev Neurobiol*. [Research Support, N.I.H., Extramural].
38 2010 Feb 15;70(3):195-203.
- 39 109. Gilbert MT, Soderstrom K. Late-postnatal cannabinoid exposure persistently elevates
40 dendritic spine densities in area X and HVC song regions of zebra finch telencephalon. *Brain*
41 *research*. [Research Support, N.I.H., Extramural]. 2011 Aug 8;1405:23-30.
- 42 110. Soderstrom K, Johnson F. Zebra finch CB1 cannabinoid receptor: pharmacology and in vivo
43 and in vitro effects of activation. *The Journal of pharmacology and experimental therapeutics*.
44 [Research Support, U.S. Gov't, P.H.S.]. 2001 Apr;297(1):189-97.
- 45 111. Whitney O, Soderstrom K, Johnson F. CB1 cannabinoid receptor activation inhibits a neural
46 correlate of song recognition in an auditory/perceptual region of the zebra finch telencephalon.
47 *Journal of neurobiology*. [Research Support, U.S. Gov't, P.H.S.]. 2003 Sep 5;56(3):266-74.
- 48 112. Soderstrom K, Tian Q. CB(1) cannabinoid receptor activation dose dependently modulates
49 neuronal activity within caudal but not rostral song control regions of adult zebra finch
50 telencephalon. *Psychopharmacology*. 2008 Aug;199(2):265-73.
- 51 113. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of
52 cannabis exposure. *Addict Biol*. [Review]. 2008 Jun;13(2):253-63.
- 53
54
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

- 1
2
3 114. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al.
4 International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their
5 ligands: beyond CB₁ and CB₂. Pharmacological reviews. [Research Support, N.I.H., Extramural
6 Research Support, N.I.H., Intramural
7 Research Support, Non-U.S. Gov't
8 Review]. 2010 Dec;62(4):588-631.
- 9 115. Egertova M, Elphick MR. Localization of CiCBR in the invertebrate chordate *Ciona*
10 intestinalis: evidence of an ancient role for cannabinoid receptors as axonal regulators of neuronal
11 signalling. The Journal of comparative neurology. [Research Support, Non-U.S. Gov't]. 2007 Jun
12 1;502(4):660-72.
- 13 116. Matias I, McPartland JM, Di Marzo V. Occurrence and possible biological role of the
14 endocannabinoid system in the sea squirt *Ciona intestinalis*. Journal of neurochemistry. 2005
15 Jun;93(5):1141-56.
- 16 117. Egertová M, Elphick MR. Localization of CiCBR in the invertebrate chordate *Ciona*
17 *intestinalis*: evidence of an ancient role for cannabinoid receptors as axonal regulators of neuronal
18 signalling. J Comp Neurol. 2007;in press.
- 19 118. Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S. Anandamide
20 (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity
21 in sea urchins by inhibiting the acrosome reaction. Proceedings of the National Academy of Sciences
22 of the United States of America. [Comparative Study
23 Research Support, Non-U.S. Gov't
24 Research Support, U.S. Gov't, P.H.S.]. 1994 Aug 2;91(16):7678-82.
- 25 119. Freeman RM, Jr., Wu M, Cordonnier-Pratt MM, Pratt LH, Gruber CE, Smith M, et al. cDNA
26 sequences for transcription factors and signaling proteins of the hemichordate *Saccoglossus*
27 *kowalevskii*: efficacy of the expressed sequence tag (EST) approach for evolutionary and
28 developmental studies of a new organism. The Biological bulletin. [Research Support, N.I.H.,
29 Extramural
30 Research Support, Non-U.S. Gov't
31 Research Support, U.S. Gov't, Non-P.H.S.]. 2008 Jun;214(3):284-302.
- 32 120. Sodergren E, Weinstock GM, Davidson EH, Cameron RA, Gibbs RA, Angerer RC, et al. The
33 genome of the sea urchin *Strongylocentrotus purpuratus*. Science. [Research Support, N.I.H.,
34 Extramural
35 Research Support, Non-U.S. Gov't
36 Research Support, U.S. Gov't, Non-P.H.S.]. 2006 Nov 10;314(5801):941-52.
- 37 121. Burke RD, Angerer LM, Elphick MR, Humphrey GW, Yaguchi S, Kiyama T, et al. A
38 genomic view of the sea urchin nervous system. Developmental biology. [Research Support, N.I.H.,
39 Extramural
40 Research Support, N.I.H., Intramural
41 Research Support, Non-U.S. Gov't]. 2006 Dec 1;300(1):434-60.
- 42 122. Stefano GB, Salzet B, Salzet M. Identification and characterization of the leech CNS
43 cannabinoid receptor: coupling to nitric oxide release. Brain research. [Comparative Study
44 Research Support, U.S. Gov't, P.H.S.]. 1997 Apr 11;753(2):219-24.
- 45 123. Elphick MR. An invertebrate G-protein coupled receptor is a chimeric
46 cannabinoid/melanocortin receptor. Brain research. 1998 Jan 5;780(1):168-71.
- 47 124. Matias I, Bisogno T, Melck D, Vandenbulcke F, Verger-Bocquet M, De Petrocellis L, et al.
48 Evidence for an endocannabinoid system in the central nervous system of the leech *Hirudo*
49 *medicinalis*. Brain Res Mol Brain Res. 2001 Mar 5;87(2):145-59.
- 50 125. Li Q, Burrell BD. Two forms of long-term depression in a polysynaptic pathway in the leech
51 CNS: one NMDA receptor-dependent and the other cannabinoid-dependent. J Comp Physiol A
52 Neuroethol Sens Neural Behav Physiol. [Research Support, N.I.H., Extramural
53 Research Support, Non-U.S. Gov't
54 Research Support, U.S. Gov't, Non-P.H.S.]. 2009 Sep;195(9):831-41.
- 55
56
57
58
59
60

- 1
2
3 126. Li Q, Burrell BD. Properties of cannabinoid-dependent long-term depression in the leech. *J*
4 *Comp Physiol A Neuroethol Sens Neural Behav Physiol*. [Research Support, N.I.H., Extramural
5 Research Support, Non-U.S. Gov't]. 2010 Nov;196(11):841-51.
6 127. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, et al. Elevation of
7 endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid
8 amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and
9 transient receptor potential vanilloid type-1 receptors. *The Journal of pharmacology and*
10 *experimental therapeutics*. [Research Support, Non-U.S. Gov't]. 2006 Mar;316(3):969-82.
11 128. Yuan S, Burrell BD. Endocannabinoid-dependent LTD in a nociceptive synapse requires
12 activation of a presynaptic TRPV-like receptor. *Journal of neurophysiology*. [Research Support,
13 N.I.H., Extramural]. 2010 Nov;104(5):2766-77.
14 129. Li Q, Burrell BD. Associative, bidirectional changes in neural signaling utilizing NMDA
15 receptor- and endocannabinoid-dependent mechanisms. *Learn Mem*. [Research Support, N.I.H.,
16 Extramural]. 2011;18(9):545-53.
17 130. Benjamin PR, Kemenes G, Kemenes I. Non-synaptic neuronal mechanisms of learning and
18 memory in gastropod molluscs. *Front Biosci*. [Research Support, Non-U.S. Gov't
19 Review]. 2008;13:4051-7.
20 131. Stefano GB, Liu Y, Goligorsky MS. Cannabinoid receptors are coupled to nitric oxide
21 release in invertebrate immunocytes, microglia, and human monocytes. *The Journal of biological*
22 *chemistry*. [Research Support, U.S. Gov't, P.H.S.]. 1996 Aug 9;271(32):19238-42.
23 132. Sepe N, De Petrocellis L, Montanaro F, Cimino G, Di Marzo V. Bioactive long chain N-
24 acylethanolamines in five species of edible bivalve molluscs. Possible implications for mollusc
25 physiology and sea food industry. *Biochimica et biophysica acta*. [Research Support, Non-U.S.
26 Gov't]. 1998 Jan 15;1389(2):101-11.
27 133. Moroz LL, Edwards JR, Puthanveettil SV, Kohn AB, Ha T, Heyland A, et al. Neuronal
28 transcriptome of *Aplysia*: neuronal compartments and circuitry. *Cell*. [Research Support, N.I.H.,
29 Extramural
30 Research Support, Non-U.S. Gov't
31 Research Support, U.S. Gov't, Non-P.H.S.]. 2006 Dec 29;127(7):1453-67.
32 134. Fleury E, Huvet A, Lelong C, de Lorgeril J, Boulo V, Gueguen Y, et al. Generation and
33 analysis of a 29,745 unique Expressed Sequence Tags from the Pacific oyster (*Crassostrea gigas*)
34 assembled into a publicly accessible database: the GigasDatabase. *BMC Genomics*. [Research
35 Support, Non-U.S. Gov't]. 2009;10:341.
36 135. Lehtonen M, Reisner K, Auriola S, Wong G, Callaway JC. Mass-spectrometric identification
37 of anandamide and 2-arachidonoylglycerol in nematodes. *Chem Biodivers*. 2008 Nov;5(11):2431-
38 41.
39 136. Lucanic M, Held JM, Vantipalli MC, Klang IM, Graham JB, Gibson BW, et al. N-
40 acylethanolamine signalling mediates the effect of diet on lifespan in *Caenorhabditis elegans*.
41 *Nature*. [Research Support, N.I.H., Extramural]. 2011 May 12;473(7346):226-9.
42 137. Montell C. *Drosophila* visual transduction. *Trends Neurosci*. 2012 Apr 10.
43 138. Leung HT, Tseng-Crank J, Kim E, Mahapatra C, Shino S, Zhou Y, et al. DAG lipase activity
44 is necessary for TRP channel regulation in *Drosophila* photoreceptors. *Neuron*. [Comparative Study
45 Research Support, N.I.H., Extramural]. 2008 Jun 26;58(6):884-96.
46 139. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V. Finding of the
47 endocannabinoid signalling system in *Hydra*, a very primitive organism: possible role in the feeding
48 response. *Neuroscience*. [Research Support, Non-U.S. Gov't]. 1999;92(1):377-87.
49 140. Chapman JA, Kirkness EF, Simakov O, Hampson SE, Mitros T, Weinmaier T, et al. The
50 dynamic genome of *Hydra*. *Nature*. [Research Support, N.I.H., Extramural
51 Research Support, Non-U.S. Gov't
52 Research Support, U.S. Gov't, Non-P.H.S.]. 2010 Mar 25;464(7288):592-6.
53
54
55
56
57
58
59
60

Evolution and Comparative Neurobiology

Maurice R. Elphick

141. Putnam NH, Srivastava M, Hellsten U, Dirks B, Chapman J, Salamov A, et al. Sea anemone genome reveals ancestral eumetazoan gene repertoire and genomic organization. *Science*.

[Comparative Study

Research Support, N.I.H., Extramural

Research Support, Non-U.S. Gov't

Research Support, U.S. Gov't, Non-P.H.S.]. 2007 Jul 6;317(5834):86-94.

For Review Only